In Review: PCMA testified in the Senate Health and Welfare Committee on H 233, which is a ban on spread pricing, private right of action, and copay coupons being applied to deductibles. After the hearing, an amendment was proposed by Senator Terrry Williams (R) to change the definition of “Maximum Allowable Cost” to include brand-name drugs. PCMA reacted quickly and provided the Chair and Committee members with concerns about the proposed change. Ultimately, the amendment was withdrawn. The committee voted to pass H 233, and it now heads to Senate Finance as a fiscal note is required on the bill. PCMA will continue to monitor and participate. We will also discuss our veto strategy on a future call.

If you have any questions, please contact Sam Hallemeier at shallemeier@pcmanet.org.